Literature DB >> 19443531

Impaired cardiac autonomic control relates to disease severity in pulmonary hypertension.

R Wensel1, C Jilek, M Dörr, D P Francis, H Stadler, T Lange, F Blumberg, C Opitz, M Pfeifer, R Ewert.   

Abstract

Pulmonary arterial hypertension (PAH) results in chronic right heart failure, which is associated with an increase in sympathetic tone. This may adversely affect cardiac autonomic control. We investigated the changes in cardiac autonomic nervous activity in relation to disease severity in patients with PAH. In 48 patients with PAH (median World Health Organization class III, pulmonary artery pressure 52+/-14 mmHg, pulmonary vascular resistance 1,202+/-718 dyn x s x cm(-5), cardiac index 2.0+/-0.8 L x min(-1) x m(-2)) and 41 controls, cardiac autonomic nervous activity was evaluated by measurement of heart rate variability (HRV) and baroreflex sensitivity. All patients underwent cardiopulmonary exercise testing (peak oxygen uptake 13.2+/-5.1 mL x kg(-1) x min(-1), minute ventilation/carbon dioxide production slope 47+/-16). In patients with PAH, spectral power of HRV was reduced in the high-frequency (239+/-64 versus 563+/-167 ms2), low-frequency (245+/-58 versus 599+/-219 ms2) and very low-frequency bands (510+/-149 versus 1106+/-598 ms2; all p<0.05). Baroreflex sensitivity was also blunted (5.8+/-0.6 versus 13.9+/-1.2 ms x mmHg(-1); p<0.01). The reduction in high-frequency (r = 0.3, p = 0.04) and low-frequency (r = 0.33, p = 0.02) spectral power and baroreflex sensitivity (r = 0.46, p<0.01) was related to the reduction in peak oxygen uptake. Patients with PAH have a marked alteration in cardiac autonomic control that is related to exercise capacity and may, therefore, serve as an additional marker of disease severity.

Entities:  

Mesh:

Year:  2009        PMID: 19443531     DOI: 10.1183/09031936.00145708

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  40 in total

Review 1.  The right ventricle and pulmonary hypertension.

Authors:  Mariëlle C van de Veerdonk; Harm J Bogaard; Norbert F Voelkel
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

2.  Kinetics of skeletal muscle O2 delivery and utilization at the onset of heavy-intensity exercise in pulmonary arterial hypertension.

Authors:  Priscila B Barbosa; Eloara M V Ferreira; Jaquelina S O Arakaki; Luciana S Takara; Juliana Moura; Rúbia B Nascimento; Luiz E Nery; J Alberto Neder
Journal:  Eur J Appl Physiol       Date:  2011-01-12       Impact factor: 3.078

3.  Value of impedance cardiography during 6-minute walk test in pulmonary hypertension.

Authors:  Adriano R Tonelli; Laith Alkukhun; Vineesha Arelli; José Ramos; Jennie Newman; Kevin McCarthy; Bohdan Pichurko; Omar A Minai; Raed A Dweik
Journal:  Clin Transl Sci       Date:  2013-09-06       Impact factor: 4.689

4.  Home Exercise Training in Children and Adolescents with Pulmonary Arterial Hypertension: A Pilot Study.

Authors:  David Zöller; Jannos Siaplaouras; Anita Apitz; Peter Bride; Michael Kaestner; Heiner Latus; Dietmar Schranz; Christian Apitz
Journal:  Pediatr Cardiol       Date:  2016-11-14       Impact factor: 1.655

5.  Severity of arterial and chronic thromboembolic pulmonary hypertension is associated with impairment of heart rate turbulence.

Authors:  Piotr Bienias; Maciej Kostrubiec; Zuzanna Rymarczyk; Dariusz Korczak; Michał Ciurzyński; Marcin Kurzyna; Adam Torbicki; Anna Fijałkowska; Piotr Pruszczyk
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-06-05       Impact factor: 1.468

6.  Role of inflammation, oxidative stress, and autonomic nervous system activation during the development of right and left cardiac remodeling in experimental pulmonary arterial hypertension.

Authors:  A Zimmer; R B Teixeira; J H P Bonetto; A C Bahr; P Türck; A L de Castro; C Campos-Carraro; F Visioli; T R Fernandes-Piedras; K R Casali; C M C Scassola; G Baldo; A S Araujo; P Singal; A Belló-Klein
Journal:  Mol Cell Biochem       Date:  2019-11-14       Impact factor: 3.396

Review 7.  Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension.

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Circulation       Date:  2015-06-09       Impact factor: 29.690

Review 8.  Pulmonary hypertension: Pathophysiology beyond the lung.

Authors:  Aline C Oliveira; Elaine M Richards; Mohan K Raizada
Journal:  Pharmacol Res       Date:  2019-11-13       Impact factor: 7.658

Review 9.  Novel therapeutic approaches to preserve the right ventricle.

Authors:  Samar Farha; Erika L Lundgrin; Serpil C Erzurum
Journal:  Curr Heart Fail Rep       Date:  2013-03

10.  Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertension.

Authors:  Omar A Minai; Quyen Nguyen; Srinivas Mummadi; Esteban Walker; Kevin McCarthy; Raed A Dweik
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.